Urcosimod (formerly known as OK-101) has been shown to be stable for over 2 and a half years in single-use ampoules used for administration of the drug to patients.

Urcosimod stable in single-use ampoules for more than 2½ years FDA requires drug to show long-term shelf stability for ...

There’s another $665 million in potential milestones and a royalty tied to the deal, which focuses on OSE-230, billed as a potentially first-in-class activator of ChemR23, a G-protein coupled ...

Urcosimod, previously known as OK-101, is a lipid conjugated chemerin peptide agonist targeting the ChemR23 receptor. It has demonstrated anti-inflammatory and pain-reducing activities in mouse ...

这些进展是在干眼症Phase 2试验完成之后进行的，在该试验中，urcosimod在多个终点指标上显示出显著的功效。目前的重点是其解决NCP的潜力，正在进行的试验作为评估其治疗这种衰弱性疾病有效性的关键。虽然该公司目前的EBITDA为负1035万美元，但分析师保持多方观点，目标价格为每股7美元。 InvestingPro 订阅者可以获取额外的见解，包括5个更多的专属ProTips和全面的财务指标。

Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response ...

NCP is a severe eye condition that causes pain and sensitivity, often resulting from nerve damage and inflammation. Urcosimod, previously known as OK-101, is a lipid conjugated chemerin peptide ...

About Urcosimod (Formerly called OK-101) Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye ...